Illinois Doctor Permanently Banned from Prescribing Controlled Drugs by DEA
Published Date: 4/25/2025
Notice
Summary
Dr. Syed Warsi from Illinois lost his medical and controlled substance licenses, so the DEA is officially revoking his registration to handle controlled substances. This means he can no longer prescribe or manage these drugs, effective immediately. If you’re a patient or partner, this change is final and means no more prescriptions from Dr. Warsi starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Doctor barred from renewing or getting new registrations
The DEA revokes Dr. Syed Warsi's registration and also denies any pending applications to renew, modify, or obtain any additional DEA registration in Illinois. The Order (revoking Certificate No. BW8048022) is effective May 27, 2025.
Patients lose access to controlled drugs
DEA Certificate of Registration No. BW8048022 for Syed Warsi, M.D. is revoked, so patients of Dr. Warsi can no longer receive prescriptions or medical handling of controlled substances from him. The Order cites that Dr. Warsi's Illinois medical and controlled-substance licenses were suspended on July 13, 2022 and remain suspended, and the revocation becomes effective May 27, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-07173, Notice of Public Meeting of the Arizona Advisory Committee
The Arizona Advisory Committee will meet online on May 2, 2025, to review and vote on an important opinion article about civil rights. This meeting affects anyone interested in Arizona’s civil rights issues and happens at 11 a.m. Arizona time. No money changes hands, but your voice and awareness matter!
Next: 2025-07175, Liberty Pharmacy Inc.; Metro Care Pharmacy Inc.; Ritecare Pharmacy Inc.; United Pharmacy Upper Darby Inc.; Decision and Order
Four pharmacies in Philadelphia had their licenses suspended because they didn’t keep proper records of controlled substances, which could risk public safety. They didn’t ask for a hearing, so their registrations were officially revoked. This means they can’t legally handle these drugs anymore, effective immediately, impacting their business and customers.